
Ask a doctor about a prescription for OLMESARTAN/AMLODIPINE AUROVITAS 40 mg/10 mg FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Olmesartan/Amlodipine Aurovitas 40 mg/10 mg Film-Coated Tablets EFG
olmesartan medoxomil/amlodipine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Olmesartan medoxomil/amlodipine contains two active substances called olmesartan medoxomil and amlodipine (as amlodipine besylate). Both substances help to control high blood pressure.
The action of both substances contributes to preventing the narrowing of blood vessels, so they relax and blood pressure decreases.
Olmesartan medoxomil/amlodipine is used to treat high blood pressure in patients whose blood pressure is not adequately controlled with olmesartan medoxomil or amlodipine alone.
Do not take Olmesartan/Amlodipine Aurovitas
If you think you may be allergic, inform your doctor before taking olmesartan medoxomil/amlodipine.
Warnings and precautions
Consult your doctor or pharmacist before starting to take olmesartan medoxomil/amlodipine.
Tell your doctorif you are taking any of the following medicines used to treat high blood pressure (hypertension):
Your doctor may check your kidney function, blood pressure, and blood electrolyte levels (e.g. potassium) at regular intervals.
See also the information under the heading “Do not take Olmesartan/Amlodipine Aurovitas”.
Tell your doctorif you have any of the following health problems:
Contact your doctor if you have severe, persistent diarrhea that causes significant weight loss. Your doctor will assess your symptoms and decide how to proceed with your blood pressure treatment.
As with any other medicine that lowers blood pressure, excessive lowering of blood pressure in patients with altered blood flow in the heart or brain may cause a heart attack or stroke. Therefore, your doctor will carefully monitor your blood pressure.
You must inform your doctor if you are pregnant or think you might be pregnant. Olmesartan medoxomil/amlodipine is not recommended at the start of pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken at this stage (see section “Pregnancy and breast-feeding”).
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking olmesartan/amlodipine. Your doctor will decide whether to continue treatment. Do not stop taking olmesartan/amlodipine on your own.
Children and adolescents (under 18 years)
Olmesartan medoxomil/amlodipine is not recommended for children and adolescents under 18 years.
Other medicines and Olmesartan/Amlodipine Aurovitas
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription.
Your doctor may need to change your dose and/or take other precautions:
If you are taking an ACE inhibitor or aliskiren (see also the information under the headings “Do not take Olmesartan/Amlodipine Aurovitas” and “Warnings and precautions”).
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Taking Olmesartan/Amlodipine Aurovitas with food and drinks
Olmesartan medoxomil/amlodipine can be taken with or without food. Take the tablets with a little liquid (such as a glass of water). If possible, take your daily dose at the same time each day, for example, at breakfast time.
People taking olmesartan medoxomil/amlodipine must not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice can cause an unpredictable increase in the blood levels of the active ingredient amlodipine, which can cause an unpredictable increase in the blood pressure-lowering effect of olmesartan medoxomil/amlodipine.
Elderly patients
If you are over 65 years old, your doctor will regularly check your blood pressure each time your dose is increased, to make sure it does not decrease too much.
Black patients
As with other similar medicines, the blood pressure-lowering effect of olmesartan medoxomil/amlodipine is somewhat smaller in black patients.
Pregnancy and breast-feeding
Pregnancy
You must inform your doctor if you are pregnant or think you might be pregnant.
Your doctor will advise you to stop taking olmesartan medoxomil/amlodipine before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of olmesartan medoxomil/amlodipine. Olmesartan medoxomil/amlodipine is not recommended at the start of pregnancy, and must not be taken when you are more than 3 months pregnant, as it may cause serious harm to your baby if taken from the third month of pregnancy onwards.
If you become pregnant while taking olmesartan medoxomil/amlodipine, inform your doctor immediately.
Breast-feeding
Tell your doctor if you are breast-feeding or about to start breast-feeding. It has been shown that amlodipine passes into breast milk in small amounts. Olmesartan medoxomil/amlodipine is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment if you wish to breast-feed, especially if your baby is newborn or premature.
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
During treatment for high blood pressure, you may feel drowsy, feel sick, or dizzy, or have a headache. If this happens, do not drive or use machines until the symptoms have gone away. Consult your doctor.
Olmesartan/Amlodipine Aurovitas contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
Olmesartan/Amlodipine Aurovitas contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per film-coated tablet, which is essentially “sodium-free”.
Follow exactly the instructions of your doctor or pharmacist for taking this medicine. If you are not sure, consult your doctor or pharmacist again.
If you take more Olmesartan/Amlodipine Aurovitas than you should
If you take more tablets than you should, you will probably experience a drop in blood pressure, accompanied by symptoms such as dizziness, and a fast or slow heart rate.
If you take more tablets than you should, or a child accidentally swallows some tablets, contact your doctor or go to the nearest emergency department immediately and take the medicine pack or this leaflet with you.
In case of overdose or accidental ingestion, call the Toxicology Information Service. Telephone 91 562 04 20, stating the medicine and the amount taken.
Excess fluid may accumulate in the lungs (pulmonary edema) causing difficulty breathing, which can develop up to 24-48 hours after ingestion.
If you forget to take Olmesartan/Amlodipine Aurovitas
If you forget to take a dose, take your normal dose the next day. Do not take a double dose to make up for forgotten doses.
If you stop taking Olmesartan/Amlodipine Aurovitas
It is important to continue taking olmesartan medoxomil/amlodipine unless your doctor tells you to stop.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. If they occur, they are often mild and do not require discontinuation of treatment.
The following adverse effects may be serious, although they affect only a small group of people:
During treatment with olmesartan medoxomil/amlodipine, allergic reactions can occur, which can affect the whole body, with inflammation of the face, mouth, and/or larynx (vocal cords), along with itching and skin rash. If this happens to you, stop taking olmesartan medoxomil/amlodipineand consult your doctor immediately.
Olmesartan medoxomil/amlodipine may cause a pronounced decrease in blood pressure, in susceptible patients, or as a result of an allergic reaction. This can cause fainting or severe dizziness. If this happens to you, stop taking olmesartan medoxomil/amlodipine, consult your doctor immediately, and remain lying down in a horizontal position.
Frequency not known (cannot be estimated from available data)
If you experience yellowing of the whites of the eyes, dark urine, itching of the skin, even if you started treatment with olmesartan medoxomil/amlodipine a long time ago, contact your doctor immediatelywho will evaluate your symptoms and decide how to continue treatment for high blood pressure.
Other possible adverse effects with olmesartan medoxomil/amlodipine:
Frequent (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Some changes in blood test results have also been observed: increased and decreased potassium levels in the blood, increased creatinine levels in the blood, increased uric acid levels, and increased liver function test values (gamma-glutamyl transferase levels).
Rare (may affect up to 1 in 1,000 people):
Adverse effects reported with the use of olmesartan medoxomil or amlodipine alone, but not with olmesartan medoxomil/amlodipine, or with a higher frequency:
Olmesartan medoxomil
Frequent (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Amlodipine
Very frequent (may affect more than 1 in 10 people):
Frequent (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Very rare (may affect up to 1 in 10,000 people):
Frequency not known (cannot be estimated from available data):
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton, blister, or label after "EXP". The expiration date is the last day of the month indicated.
Store below 30°C.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and unused medicines in the pharmacy's SIGRE collection point. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Olmesartan/Amlodipine Aurovitas40 mg/10 mg film-coated tablets EFG
Core of the tablet:microcrystalline cellulose (101 and 102), pregelatinized corn starch, sodium croscarmellose, anhydrous colloidal silica, lactose, magnesium stearate.
Coating of the tablet:partially hydrolyzed polyvinyl alcohol, titanium dioxide (E171), talc, macrogol 4000.
Appearance and Package Contents
Film-coated tablet.
White to off-white, round, biconvex film-coated tablets with "M" engraved on one side and "29" on the other side.
Olmesartan/Amlodipine Aurovitas 40 mg/10 mg film-coated tablets EFG are available in blisters.
Package Sizes:
14, 28, 30, 56, 90, and 98 film-coated tablets.
Not all package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
Manufacturer
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
O
Generis Farmacêutica, S.A.
Rua João de Deus, 19
2700-487 Amadora
Portugal
This medicine is authorized in the Member States of the European Economic Area under the following names:
Belgium: Olmesartan/Amlodipine AB 40 mg/10 mg film-coated tablets/comprimés pelliculés/Filmtabletten
Germany: Olmesartan/Amlodipin PUREN 40 mg/10 mg film-coated tablets
Netherlands: Olmesartan medoxomil/Amlodipine Aurobindo 40 mg/10 mg film-coated tablets
Portugal: Amlodipine + Olmesartan medoxomil Generis
Spain: Olmesartán/Amlodipino Aurovitas 40 mg/10 mg film-coated tablets EFG
Date of the Last Revision of this Leaflet:May 2025
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
The average price of OLMESARTAN/AMLODIPINE AUROVITAS 40 mg/10 mg FILM-COATED TABLETS in October, 2025 is around 21.43 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for OLMESARTAN/AMLODIPINE AUROVITAS 40 mg/10 mg FILM-COATED TABLETS – subject to medical assessment and local rules.